This compound is a deuterated active pharmaceutical ingredient, a labeled derivative of a carbazole-based molecule where multiple hydrogen atoms have been replaced with deuterium. Its primary significance lies in its use as a research compound for pharmaceutical manufacturing and development.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1219798-86-3
Rifaximin-d6 (Major)
pharmaceutical raw material
Urapidil-d3 (methoxy-d3)
pharmaceutical raw material
(1S,3R,4S)-quinuclidin-3-yl (S)-1-(phenyl-d5)-3,4-dihydroisoquinoline-2(1H)-carboxylate
pharmaceutical raw material
Kenalog
pharmaceutical raw material
Donepezil-d4 (hydrochloride)
pharmaceutical raw material
HYDROCHLOROTHIAZIDE-3,3-D2
pharmaceutical raw material
Propafenone (D7 hydrochloride)
pharmaceutical raw material
Betaxolol-d7 (hydrochloride)
pharmaceutical raw material
3-[[4,5-dideuterio-2-(trideuteriomethyl)imidazol-1-yl]methyl]-9-methyl-2,3-dihydro-1H-carbazol-4-one
FELGMEQIXOGIFQ-OIYGLIEASA-N
[2H]C1=C(N(C(=N1)C([2H])([2H])[2H])CC2CCC3=C(C2=O)C4=CC=CC=C4N3C)[2H]
—